Market News AIOpen the app

VNDA stock news · Vanda Pharmaceuticals Inc.

Stories about Vanda Pharmaceuticals Inc. (VNDA) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for VNDA

Follow Vanda Pharmaceuticals Inc. (VNDA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VNDA
Free on the App Store and Google Play, or on the web.
  1. Nov 20, 2026, 7:08 AM ET · Rules

    Vanda Pharmaceuticals has signed a deal to settle a patent dispute, letting MSN sell a generic version of HETLIOZ LQ.

    Good for VNDA

    Vanda settled a patent case, allowing MSN to sell its generic version starting in Q1 2040, with earlier entry possible in some cases. This favors Vanda by delaying competition.

  2. Oct 15, 2026, 9:03 AM ET · Market

    Vanda Pharmaceuticals says its new anxiety drug didn’t meet key goals in testing.

    Bad for VNDA

    Vanda's Phase 3 anxiety-drug study missed its main and second goals, failing to confirm earlier encouraging results. This weakens the outlook for VQW-765.

  3. Oct 14, 2026, 5:18 PM ET · Market

    12 health care stocks changed a lot in prices after the market closed on Wednesday.

    Neutral

    Vanda Pharmaceuticals shares fell 9.72% to $3.81 after hours, but the report gives no company news, so the business view is unchanged.

  4. Sep 30, 2026, 9:14 AM ET · Market

    Vanda hopes to be the first to get a drug approved for people with sleep problems.

    Good for VNDA

    Vanda reported that HETLIOZ helped adults fall asleep earlier in a Phase 3 trial. The result supports a favorable outlook, though FDA approval is still pending.